Triple-AAV intein-mediated gene therapy ameliorates dystrophic phenotype in MDC1A mice
Molecular Therapy · 2026-10 · 34 (10) · 5697-5709
DOI: 10.1016/j.ymthe.2026.07.045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026-10. Verfasst von Núria Rafel-Millan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain; SpliceBio, 08028 Barcelona, Spain. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Laminin, Genetic Vectors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Agencia Estatal de Investigación, Generalitat de Catalunya.
Abstract (Originalsprache)
Several therapies using adeno-associated viruses (AAVs) as a gene delivery tool have received marketing approval in the past. However, potential applications of AAVs are limited by their restricted gene packaging capacities (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain; SpliceBio, 08028 Barcelona, Spain.
- Department of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.
- Department of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain; Vall D'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain.
- Vall D'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain.
- Institut de Neurociènces (INc), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; Vall D'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain.
- Institut de Neurociènces (INc), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; Vall D'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain; Institució Catalana de Recerca I Estudis Avançats, 08010 Barc…
Förderung
- Agencia Estatal de Investigación
- Generalitat de Catalunya
Zitieren
APA
Rafel-Millan, N., Bayod-Girón, C., Pallarès-Masmitjà, M., Fernández-Avilés, C., Figuereo-Moya, K., Edo, Á., Chillón, M., Vila-Perelló, M., Frutos, S., & Güell, M. (2026). Triple-AAV intein-mediated gene therapy ameliorates dystrophic phenotype in MDC1A mice. Molecular Therapy, 34(10), 5697-5709. https://doi.org/10.1016/j.ymthe.2026.07.045
Vancouver
Rafel-Millan N, Bayod-Girón C, Pallarès-Masmitjà M, Fernández-Avilés C, Figuereo-Moya K, Edo Á, et al. Triple-AAV intein-mediated gene therapy ameliorates dystrophic phenotype in MDC1A mice. Molecular Therapy. 2026;34(10):5697-5709. doi:10.1016/j.ymthe.2026.07.045
BibTeX
@article{RafelMillan2026,
author = {Rafel-Millan, Núria and Bayod-Girón, Carles and Pallarès-Masmitjà, Maria and Fernández-Avilés, Cristina and Figuereo-Moya, Keilisa and Edo, Ángel and Chillón, Miguel and Vila-Perelló, Miquel and Frutos, Silvia and Güell, Marc},
title = {Triple-AAV intein-mediated gene therapy ameliorates dystrophic phenotype in MDC1A mice},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {10},
pages = {5697--5709},
doi = {10.1016/j.ymthe.2026.07.045}
}
EUVIMED